SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synaptogenix, Inc. on September 22, 2023. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. The report addresses Item 5.03 regarding amendments to the Certificate of Designations for the Company's Series B Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure amendments rather than financial performance results.
Material Changes
On September 22, 2023, the Company filed a Certificate of Amendment to the Certificate of Designations for its Series B Convertible Preferred Stock. This amendment modifies the terms regarding payments to investors in the event of an "Equity Conditions Failure." Key changes include:
- Permitting mutual agreement between the Company and investors on whether monthly amortization payments are made in cash or common stock.
- Allowing flexibility in the methodology for calculating true-up shares and conversion prices for accelerated conversions.
- Enabling the potential application of a premium if true-up shares are paid in cash instead of stock.
The primary objective of this amendment is to provide the Company with additional flexibility to use common stock instead of cash for amortization payments, thereby supporting efforts to conserve cash.
Guidance, Outlook, and Risks
Management commentary indicates that the amendment is designed to support cash conservation efforts. The filing does not contain forward-looking financial guidance, specific risk factors beyond the context of the amendment, or details on unusual items. The full text of the Amendment is incorporated by reference as Exhibit 3.1.
Investor Verification Checklist
- Review Exhibit 3.1 (Certificate of Amendment) for the complete legal terms and limitations regarding the new payment flexibility.
- Verify the current status of any "Equity Conditions Failure" that may trigger these new payment options.
- Assess the potential dilution impact on common shareholders if the Company elects to make amortization payments in stock rather than cash.
- Confirm the total outstanding amount of Series B Convertible Preferred Stock to understand the scale of potential cash or stock obligations.